Why the study?
Does [TIMP-2]•[IGFBP7] biomarker testing improve the management of acute kidney injury risk in critical care patients?
Design
Expert panel guidance
Authors
Loading...
Supports biomarker-guided AKI management in critical care; extends consensus with actionable risk-stratification protocols.
Does [TIMP-2]•[IGFBP7] biomarker testing improve the management of acute kidney injury risk in critical care patients?
[TIMP-2]•[IGFBP7] biomarker testing can guide clinical management in critical care by identifying patients who need nephrotoxic drug and fluid management versus those suitable for fast-track protocols.
Guzzi et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: